$0.86 EPS Expected for Lannett Company, Inc. (LCI) This Quarter

Wall Street analysts expect Lannett Company, Inc. (NYSE:LCI) to post $0.86 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Lannett’s earnings, with the lowest EPS estimate coming in at $0.82 and the highest estimate coming in at $0.93. Lannett reported earnings per share of $0.92 during the same quarter last year, which suggests a negative year over year growth rate of 6.5%. The firm is scheduled to report its next earnings report on Wednesday, February 7th.

According to Zacks, analysts expect that Lannett will report full-year earnings of $3.14 per share for the current fiscal year, with EPS estimates ranging from $3.00 to $3.38. For the next financial year, analysts anticipate that the business will post earnings of $3.04 per share, with EPS estimates ranging from $2.55 to $3.39. Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Lannett.

Lannett (NYSE:LCI) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.08. The firm had revenue of $155.00 million for the quarter, compared to analyst estimates of $153.62 million. Lannett had a net margin of 6.67% and a return on equity of 18.23%. Lannett’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.77 earnings per share.

A number of equities analysts recently weighed in on LCI shares. Zacks Investment Research upgraded shares of Lannett from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a research report on Monday, December 11th. BMO Capital Markets lifted their target price on shares of Lannett from $20.00 to $22.00 and gave the stock a “market perform” rating in a research note on Monday, November 13th. ValuEngine raised shares of Lannett from a “hold” rating to a “buy” rating in a research note on Saturday, November 25th. Oppenheimer reaffirmed a “hold” rating on shares of Lannett in a research note on Monday, December 11th. Finally, Goldman Sachs Group started coverage on shares of Lannett in a research note on Wednesday. They set a “neutral” rating and a $21.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company. Lannett has a consensus rating of “Hold” and a consensus target price of $23.17.

Lannett (NYSE LCI) opened at $23.20 on Friday. The firm has a market cap of $874.64, a PE ratio of 20.71, a P/E/G ratio of 1.46 and a beta of 2.85. Lannett has a 52-week low of $14.90 and a 52-week high of $30.35. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.90 and a current ratio of 2.52.

In other news, major shareholder David Farber sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $25.01, for a total value of $250,100.00. Following the sale, the insider now directly owns 4,171,269 shares of the company’s stock, valued at approximately $104,323,437.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Arthur P. Bedrosian sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $26.75, for a total transaction of $1,337,500.00. Following the completion of the sale, the chief executive officer now directly owns 636,616 shares in the company, valued at $17,029,478. The disclosure for this sale can be found here. Insiders have sold 140,000 shares of company stock worth $3,681,091 over the last ninety days. 14.72% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. CS Mckee LP raised its stake in shares of Lannett by 0.6% in the 2nd quarter. CS Mckee LP now owns 35,400 shares of the company’s stock valued at $722,000 after acquiring an additional 200 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Lannett by 1.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,366 shares of the company’s stock valued at $456,000 after acquiring an additional 297 shares during the period. Royal Bank of Canada raised its stake in shares of Lannett by 10.6% in the 2nd quarter. Royal Bank of Canada now owns 18,374 shares of the company’s stock valued at $374,000 after acquiring an additional 1,756 shares during the period. State of Tennessee Treasury Department raised its stake in shares of Lannett by 6.9% in the 2nd quarter. State of Tennessee Treasury Department now owns 27,848 shares of the company’s stock valued at $568,000 after acquiring an additional 1,795 shares during the period. Finally, Nationwide Fund Advisors raised its stake in shares of Lannett by 7.3% in the 2nd quarter. Nationwide Fund Advisors now owns 26,349 shares of the company’s stock valued at $538,000 after acquiring an additional 1,800 shares during the period. 97.14% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/28/0-86-eps-expected-for-lannett-company-inc-lci-this-quarter.html.

About Lannett

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Get a free copy of the Zacks research report on Lannett (LCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lannett (NYSE:LCI)

Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply